Skip to content

News

Latest news

Updates on SYNGAP1 research, the community in Portugal and our organisation's activities.

Latest

Latest news

View all
  • Conference

    CURE SYNGAP1 Conference in Denver: 3–4 December

    The 2026 CURE SYNGAP1 Conference takes place on 3–4 December at the Grand Hyatt Denver, USA. The draft programme includes research, new therapies, clinical trial readiness and a session on the Phase 1/2 ASCEND trial. Registration closed on 31 October. Visit the official event page for the programme and further details.

  • Clinical trials

    ASCEND trial approved in the European Union

    CAMP4 Therapeutics received approval from regulatory authorities and ethics committees in several EU countries for the Phase 1/2 ASCEND trial of CMP-002 in patients with SYNGAP1-related disorder. First patient dosing is expected by the end of 2026, with initial data expected in the first half of 2028.

  • Census

    SYNGAP1 Census 2026: 1,806 cases worldwide

    The number of people diagnosed with SYNGAP1 reached 1,806 cases worldwide in the second quarter of 2026. That is 45 more cases than the previous quarter. Source: Cure SYNGAP1, Census, Citizen Health.

  • Clinical trials

    CAMP4 starts clinical trial for SYNGAP1

    CAMP4 Therapeutics received clearance in Australia and Argentina to start the first human trial of an antisense (ASO) therapy targeting SYNGAP1. The trial has since expanded to the United Kingdom and the European Union.

  • Research

    New therapy reduces seizures in SYNGAP1 model

    New CAMP4 preclinical data show that the therapy significantly reduced the frequency and severity of epileptic seizures in a SYNGAP1 animal model. The results reinforce the potential of this approach to treat epilepsy and other symptoms associated with SYNGAP1 deficiency.

  • Diagnosis

    13 people diagnosed with SYNGAP1 in Portugal

    Cure SYNGAP1 Portugal's provisional registry currently identifies 13 people diagnosed with SYNGAP1 in the country. Every registration helps make Portugal more visible to international research.

Get news about SYNGAP1 and research.

A short newsletter, no spam. You can unsubscribe at any time.

Continue

Where to go next

Explore the main areas of the site: about the condition, family support, research and how to help.